Citius Pharmaceuticals Enters Material Definitive Agreement
Ticker: CTXR · Form: 8-K · Filed: Sep 13, 2024 · CIK: 1506251
Sentiment: neutral
Topics: material-agreement
Related Tickers: CTRS
TL;DR
CTRS signed a big deal, details TBD.
AI Summary
Citius Pharmaceuticals, Inc. announced on September 9, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but indicates it is a significant event for the company.
Why It Matters
This filing signifies a potentially significant development for Citius Pharmaceuticals, which could impact its future operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty and potential risk.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- September 9, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Citius Pharmaceuticals?
The filing does not specify the nature of the material definitive agreement.
Who is the counterparty to the material definitive agreement?
The filing does not disclose the identity of the counterparty to the agreement.
What are the key financial terms or obligations associated with this agreement?
The filing does not provide any details regarding the financial terms or obligations of the agreement.
When was the agreement officially entered into?
The agreement was entered into on September 9, 2024, which is the date of the earliest event reported.
Does this agreement represent a significant change in Citius Pharmaceuticals' business operations?
The filing indicates it is a 'Material Definitive Agreement,' suggesting it is significant, but the specific impact on business operations is not detailed.
Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-09-13 08:30:09
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CTXR Nasdaq Capital Marke
Filing Documents
- ea0214420-8k_citiuspharma.htm (8-K) — 25KB
- 0001213900-24-078288.txt ( ) — 193KB
- ctxr-20240909.xsd (EX-101.SCH) — 3KB
- ctxr-20240909_lab.xml (EX-101.LAB) — 33KB
- ctxr-20240909_pre.xml (EX-101.PRE) — 22KB
- ea0214420-8k_citiuspharma_htm.xml (XML) — 4KB
01. Entry into a Material Definitive
Item 1.01. Entry into a Material Definitive Agreement. Pending further discussions with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's"), Dr. Reddy's agreed to a partial deferral without penalty of a milestone payment by Citius Oncology, Inc., which was triggered upon regulatory approval of LYMPHIR TM by the U.S. Food and Drug Administration and due on September 9, 2024, pursuant to the terms of the Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy's and Citius Pharmaceuticals, Inc. (the "Asset Purchase Agreement"). Citius Pharmaceuticals, Inc. (the "Company") is a guarantor of the obligations of Citius Oncology, Inc. under the Asset Purchase Agreement. Except as set forth above, all other terms, conditions and rights of the Asset Purchase Agreement remain in full force and effect, which was described in the Current Report on Form 8-K filed by the Company on September 7, 2021 and was filed as an exhibit to the Annual Report on Form 10-K filed by the Company on December 15, 2021. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Citius Pharmaceuticals, Inc. Date: September 13, 2024 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2